DFN-PA.TO
Dividend 15 Split Corp
TorontoCADEQUITY
DELAYED
Last price
10.88
▲ 0.02 (0.18%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
10.86
Day high
10.88
Day low
10.85
Volume
27.48K
Market cap
—
P/E (TTM)
—
52W range
9.90 – 10.88
Free account
3 more panels on DFN-PA.TO open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $343.74M | $470.01M | -$35.25M | $63.03M | -26.9% |
| Operating revenue | $343.74M | $470.01M | -$35.25M | $63.03M | -26.9% |
| Selling, general & admin | $1.60M | $1.82M | $1.67M | $2.58M | -12.2% |
| Total operating expense | $3.54M | $3.37M | $3.20M | $4.16M | +5.2% |
| Pre-tax income | $340.20M | $466.64M | -$38.46M | $58.87M | -27.1% |
| Net income | $340.20M | $466.64M | -$38.46M | $58.87M | -27.1% |
| Net income to common | $257.50M | $399.46M | -$114.27M | -$1.70M | -35.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $246.41M | $202.27M | $295.39M | $286.41M | +21.8% |
| Total assets | $2.55B | $2.13B | $1.80B | $1.74B | +20.0% |
| Total liabilities | $1.46B | $1.28B | $1.24B | $1.08B | +14.3% |
| Shareholder equity | $1.09B | $849.09M | $554.58M | $654.46M | +28.6% |
| Net tangible assets | $1.09B | $849.09M | $554.58M | $654.46M | +28.6% |
| Shares issued | 148.93M | 124.72M | 119.40M | 105.69M | +19.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $257.50M | $399.46M | -$114.27M | -$1.70M | -35.5% |
| Change in working capital | -$213.23K | $1.10M | -$1.77M | -$736.92K | -119.3% |
| Operating cash flow | -$40.61M | $2.74M | -$63.28M | $59.89M | -1,580.7% |
| Share buybacks | -$82.29M | -$17.52M | -$13.98M | $0 | -369.8% |
| Dividends paid | -$250.86M | -$189.60M | -$166.08M | -$169.09M | -32.3% |
| Financing cash flow | $84.75M | -$95.86M | $72.26M | $75.93M | +188.4% |
| Free cash flow | -$40.61M | $2.74M | -$63.28M | $59.89M | -1,580.7% |
| End cash position | $246.41M | $202.27M | $295.39M | $286.41M | +21.8% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2025-11-30 | 2025-05-31 | 2024-11-30 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $246.41M | $191.35M | $202.27M | +28.8% |
| Total assets | $2.55B | $2.17B | $2.13B | +17.6% |
| Total liabilities | $1.46B | $1.32B | $1.28B | +10.8% |
| Shareholder equity | $1.09B | $851.56M | $849.09M | +28.3% |
| Net tangible assets | $1.09B | $851.56M | $849.09M | +28.3% |
| Shares issued | 148.93M | 133.89M | 124.72M | +11.2% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
—
—
SMA 20
—
—
SMA 50
—
—
SMA 100
—
—
SMA 200
—
—
EMA 12
—
—
EMA 26
—
—
EMA 50
—
—
RSI (14)
—
—
MACD (12,26,9)
—
Hist —
ATR (14)
—
—
Realised vol 30D
—
Annualised
Bollinger upper
—
20, 2σ
Bollinger lower
—
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
—
—
Correlation to SPY
—
—
Realised vol 30D
—
Annualised
Market vol 1Y
—
SPY, annualised
Max drawdown 1Y
—
Peak to trough
Max drawdown 5Y
—
Peak to trough
ATR 14
—
Average true range
Beta (reported)
—
5Y monthly, from filing
Headlines
A $30 Billion Reason Why Nvidia Stock In Focus
GuruFocus.com · 3m ago
Arbutus Biopharma Launches $230 Million Tender Offer for Common Shares
MT Newswires · 4m ago
Treasury’s $950B cash account seen funding bond buyback surge
Investing.com · 5m ago
Laser Photonics Secures $1.05 Million Order from U.S. Pharmaceutical Manufacturer for High-Speed Tablet Drilling System
ACCESS Newswire · 7m ago
Why this analyst predicts Circle stock could surge 75%
Yahoo Finance · 8m ago
Special Committee of Better Home & Finance Issues Statement on Leadership and Operating Progress
Business Wire · 8m ago
CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy
GlobeNewswire · 8m ago
Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs
Business Wire · 8m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.